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esponsibility of Xi’Abstract A validated ultra-performance liquid chromatography mass spectrometric method (UPLC–MS/
MS) was used for the simultaneous quantitation of candesartan (CN) and hydrochlorothiazide (HCT) in
human plasma. The analysis was performed on UPLC–MS/MS system using turbo ion spray interface.
Negative ions were measured in multiple reaction monitoring (MRM) mode. The analytes were extracted
using a liquid–liquid extraction (LLE) method by using 0.1 mL of plasma volume. The lower limit of
quantitation for CN and HCT was 1.00 ng/mL whereas the upper limit of quantitation was 499.15 ng/mL and
601.61 ng/mL for CN and HCT respectively. CN d4 and HCT-
13Cd2 were used as the internal standards for
CN and HCT respectively. The chromatography was achieved within 2.0 min run time using a C18 Pheno-
menex, Gemini NX (100 mm 4.6 mm, 5 mm) column with organic mixture:buffer solution (80:20, v/v) at
a ﬂow rate of 0.800 mL/min. The method has been successfully applied to establish the bioequivalence of
candesartan cilexetil (CNC) and HCT immediate release tablets with reference product in human subjects.
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an Jiaotong University.1. Introduction
Candesartan cilexetil (CNC) is an inactive prodrug of candesartan (CN)
which is a new generation angiotensin II type 1 receptor blocker
(ARB) mainly used for the treatment of hypertension. CNC is
hydrolyzed completely by esterase in the intestinal wall during
absorption to the active CN moiety during absorption from the
gastrointestinal tract [1]. Chemically, it is described as (7)-1-Hydro-
xyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-7-benzimida-
zolecarboxylate, cyclohexyl carbonate (ester). The use of a prodrugvier B.V. All rights reserved.
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national committee on prevention, detection, evaluation, and treatment
of high blood pressure suggests that combination therapy should
typically comprise of a thiazide-type diuretic as a ﬁrst-line therapy for
stage 2 hypertension [2]. The combination of an ARB and a low-dose
diuretic exerts a synergistic effect in terms of both efﬁcacy and
minimization of the side effects owing to their complementary
mechanisms of action [3]. Hydrochlorothiazide (HCT) is one of the
most commonly used diuretic drugs along with ARBs. It reduces the
amount of water in the body by increasing the ﬂow of urine, which
helps lower the blood pressure. Various studies conducted on the
combination of HCT and CNC have shown enhanced blood pressure
control as compared to the CNC monotherapy [4–6]. The formulation
of CNC and HCT is available in combination with trade name Atacand
HCTs in different strengths in the form of tablets. The available
strengths for CNC+HCT are 16+12.5 mg, 32+12.5 mg and 32
+25 mg. Although some literatures for the quantitation of CN and
HCT alone or in combination of other drugs are available [7–12], no
simultaneous sensitive bioanalytical method has been published that
could be applied for bioequivalence studies of human subject samples
for all available dose strengths of CN+HCT combination. A recent
report for the simultaneous quantiﬁcation of CN and HCT by using
liquid chromatography mass spectrometry (LC–MS/MS) could only
be applied for the bioequivalence of 16+12.5 mg dose strength due to
its very low validated calibration curve range [13]. So, the aim of this
study was the development and validation of bioanalytical method for
the simultaneous analysis of CN and HCT by using UPLC–MS/MS
which could be applied easily on all available dose strengths of
Atacand HCTs. This developed method is rapid, selective with good
sensitivity, having a shorter analysis run time (2.0 min) and requires a
very low plasma volume (0.1 mL) for each analysis. The method has
been successfully applied to establish the bioequivalence of CNC and
HCT 32+25 mg in-house developed immediate release tablets with
reference product [Atacand HCTs (CNC−HCT) 32+25 mg immedi-
ate release tablets of Astra Zeneca LP, Wilmington] in healthy adult,
human subjects, under fasting conditions.2. Experimental
2.1. Chemicals and materials
Working standards namely CN (99.44%), HCT (100.00%) and
CN d4 (99.21%) (IS1) were procured from Clearsynth Lab. Pvt.
Ltd., India, while HCT-13Cd2 (97.00%) (IS2) was obtained from
Splendid Lab., India. Control buffered di-potassium salt of
ethylene diamine tetra acetic acid (K2EDTA) human plasma was
procured from Mediplas Laboratories, Hyderabad, India. All other
reagents/chemicals were of AR grade.
2.2. LC–MS/MS instrumentation and settings
A WATERS ultra-performance liquid chromatography (UPLC)
system (Milford, MA, USA) with Phenomenex, Gemini NX C18
100 mm × 4.6 mm, 5 mm column was used in this study. The
mobile phase consisted of organic mixture:buffer solution (80:20,
v/v) (preparation is discussed in Section 2.4). The autosampler
temperature was maintained at 5 1C and the ﬂow rate was set at
0.800 mL/min. Ionization and detection of analyte and IS were
performed on a triple quadrupole mass spectrometer, API-4000
Q-trap (MS/MS) equipped with turbo ion spray, from MDS Sciex
(Toronto, Canada) operated in the negative ion mode. Quantitationwas done using MRM mode to monitor protonated precursor-
product ion transition of m/z 439.4-309.0, 295.9-204.8,
443.1-312.0 and 298.8-205.9 for CN, HCT, CN d4 and HCT
13Cd2, respectively. All the parameters of UPLC and MS/MS were
controlled by analyst software version 1.5.1. The source dependent
parameters maintained for analytes and internal standards were
GS1 (nebulizer gas): 45 psi, GS2 (heater gas): 55 psi, ion spray
voltage (ISV): −2000 V, turbo heater temperature (TEM): 475 1C,
entrance potential (EP): −10 V, collision activation dissociation
(CAD): 6 psi, and curtain gas (CUR): 25 psi. The compound
dependent parameters like declustering potential (DP), collision
energy (CE) and cell exit potential (CXP) were optimized at −50,
−29 and −6 V for CN, −50, −31 and −18 V for IS1, −92, −33
and −15 V for HCT and −92, −33 and −9 V for IS2, respectively.
2.3. Preparation of standard stock and plasma samples
The standard stock solutions of CN (1 mg/mL), HCT (1 mg/mL), IS1
(1 mg/10 mL) and IS2 (1 mg/10 mL) were prepared by dissolving in
requisite amount of methanol. The further dilutions from the stock
solutions were prepared by using diluent solution (methanol:milli-Q
water in the ratio of 50:50) for spiking in plasma to obtain the required
calibration curve (CC) standards and quality control (QC) samples
concentration. All the samples were protected from light during
preparation, storage and handling. Calibration curve standards consist-
ing of a set of eight non-zero concentrations of 1.00, 2.00, 62.93,
125.61, 225.12, 324.15, 425.57 and 499.15 ng/mL were prepared for
CN while concentrations of 1.00, 2.00, 75.02, 149.44, 270.73, 390.05,
511.37 and 601.61 ng/mL were prepared for HCT. The quality control
samples for CN consisting of concentrations for lower limit of
quantitation quality control (LLOQ QC¼1.00 ng/mL), low quality
control (LQC¼2.75 ng/mL), medium quality control (MQC¼249.66
ng/mL) and high quality control (HQC¼411.44 ng/mL) were pre-
pared. While for HCT LLOQ QC 1.00 ng/mL, LQC 2.74 ng/mL,
MQC 301.90 ng/mL and HQC 495.12 ng/mL were also prepared.
After bulk spiking, 200 mL of spiked plasma samples was pipetted out
in pre-labeled polypropylene tubes. The calibration curve standards and
quality control samples were logged in ultra low temperature deep
freezer (temp. range: −55 1C to −75 1C) except 30 samples each of
LQC and HQC which were transferred for storage in cell frost deep
freezer (temp. range: −17 1C to −27 1C) for the generation of long
term stability at −2275 1C. These samples were used for performing
the method validation.
2.4. Preparation of mobile phase and liquid–liquid
extraction method
Buffer solution A (5 mM ammonium acetate) was prepared by
weighing approximately 385 mg of ammonium acetate in a 1000 mL
reagent bottle followed by the addition of 1000 mL milli-Q water
and ﬁltered through a 0.22 mm membrane ﬁlter. Finally, the pH
was adjusted with liquid ammonia to 7.570.1. Organic mixture
was prepared as a mixture of methanol:acetonitrile in the ratio of
15:85 v/v (Solution B). Mobile phase was prepared by adding buffer
solution A and solution B in the ratio of 80:20 (v/v). The solutions were
used within 7 days from the date of preparation. A set of calibration
curve standards and quality control samples were withdrawn from the
deep freezer and allowed to thaw at room temperature in a water bath.
100 mL of plasma from the pre-labeled polypropylene tubes was
aliquoted into labeled ria vials and 50 mL of internal standard dilution
(IS1¼400 ng/mL and IS2¼500 ng/mL) was added and vortexed.
200 mL of formic acid:milli-Q water solution in the ratio of 99.500.5
B. Singh et al.146(v/v) (solution C) was then added and samples were vortexed. 2 mL of
extraction solution (tert-butyl-methyl-ether:dichloromethane:70:30, v/v
was added and samples were vortexed for approximately 5 min. The
samples were ﬂash freezed for 1–2 min, supernatant was decanted off
and evaporated to dryness at 40 1C at constant pressure in nitrogen
evaporator. Finally, the dried samples were reconstituted with 200 mL of
mobile phase and transferred into UPLC vials for analysis.
2.5. Method validation
The method was validated for selectivity, sensitivity, linearity, matrix
effect, precision, accuracy, recovery and stability of analytes under
different processing and storage conditions as per the USFDA guide-
lines [14]. The results of various stabilities (i.e., stock dilution stability
at refrigerator temperature and room temperature, photo degradation
test in light and dark and standard stock solution stability in refrigerator,
auto sampler stability, reinjection reproducibility, freeze-thaw stability,
long term stability at −65710 1C and at −2275 1C, reagent stability,
bench top stability, dry ice stability, dry extract stability, extended
bench top stability, wet extract stability in refrigerator, lipemic and
haemolysed plasma stability), blood stability, effect of potentially
interfering drugs, dilution integrity, recovery, ion suppression through
infusion, ruggedness, robustness and extended batch veriﬁcation met
the acceptance criteria as per the USFDA guidelines [15].
Selectivity of the method for endogenous substances was accessed
at LLOQ level for CN and HCT in eight lots of normal plasma, four
lots of lipemic plasma and four lots of haemolysed plasma containing
K2EDTA as an anticoagulant. Sensitivity of the method was deter-
mined in six LLOQ samples for CN and HCT by quantitating against a
calibration curve. The calibration curve data of three precision and
accuracy batches were subjected for goodness of ﬁt analysis. The back-
calculated concentrations of calibration curve standards using 1/x and
1/x2 weighing were considered for ﬁnding the best ﬁt for regression.
Linearity was calculated using a regression equation with a weighting
factor of 1/x2 for drug to IS concentration to produce the best ﬁt for the
concentration–detector response relationship for CN and HCT. Matrix
effect was accessed at two concentration levels (LQC and HQC) in
normal, lipemic and haemolysed plasma. For matrix effect in normal,
lipemic and haemolysed plasma, 12 blank samples were processed
from six normal plasma lots, six blank samples from three lipemic
plasma lots and six blank samples from three haemolysed plasma lots.
Two aliquots were used from each plasma lot and these post-extracted
dried blank samples of matrix effect were prepared by reconstituting
with the neat solutions containing CN and HCT at LQC and HQC
concentrations representing the ﬁnal extracted concentration for both
the analytes as well as internal standards. The comparison samples
were the same neat solutions prepared in mobile phase at LQC and
HQC levels containing CN and HCT. Matrix effect was calculated as
per the following formula:
Matrix factor¼ ðPeak response in the presence of matrix ionsÞ
=ðPeak response in the absence of matrix ionsÞ
% Matrix effect¼ ð1−Mean of matrix factorÞ  100
The precision of the assay was calculated as percent coefﬁcient
of variation over the concentration range of LLOQ QC, LQC,
MQC and HQC samples. The accuracy of the assay was calculated
as the ratio of the mean values of the LLOQ QC, LQC, MQC and
HQC samples to their respective nominal values. Intra-day
precision and accuracy were calculated by analyzing the six
replicates of quality control samples at four concentration levelswithin the single analytical run while the inter-day precision and
accuracy were calculated by analyzing the 18 replicates of quality
control samples at four concentration levels from three analytical
runs on two consecutive days of validation.
To access the recovery of the extraction method followed for
extraction of analytes and internal standards the aqueous comparison
samples (LQC, MQC and HQC) were prepared by adding 40 mL
aqueous dilution (20 mL aqueous dilution each of CN and HCT) from
each respective quality control, 500 mL of IS dilution (approximately
400 ng/mL for IS1 and 500 ng/mL for IS2) and 3460 mL of mobile
phase (representing 100% extraction). The aqueous samples (LQC,
MQC and HQC) of CN and HCT were compared against six sets of
extracted LQC, MQC and HQC samples. Recovery of internal
standard was also compared at LQC, MQC and HQC levels.
% Recovery¼ ðMean peak area response of extracted sampleÞ
=ðCorrected mean peak area response of unextracted sampleÞ100
The stability of CN and HCT in plasma was performed during their
processing and storage. Bench top stability of CN and HCT was
determined for 22 h using six sets each of LQC and HQC samples
while extended bench top stability was determined for 7 h in spiked
LQC and HQC samples at every step of sample processing. The freeze-
thaw stability for the analytes was determined after completion of ﬁve
freeze–thaw cycles by using six sets of LQC and HQC samples. Long
term stability (at −65710 1C and −2275 1C) was carried out in
plasma for 22 days. To access each kind of stability for CN and HCT
in plasma six sets of LQC and HQC samples were processed and
analyzed after required storage time against the freshly spiked
calibration curve standards and freshly spiked quality control samples
(freshly spiked comparison QC samples were prepared from the fresh
stock solution of analytes at LQC and HQC levels) to calculate the %
change. Stock dilution stability in refrigerator for CN, HCT, IS1 and
IS2 was carried out for 22 days while stock dilution stability at room
temperature and at 2–8 1C was carried out for 26 h. Photo degradation
test samples of analytes and IS were kept for 26 h in light and dark. For
the aqueous medium stability (except plasma) studies i.e., stock dilution
stability at 2–8 1C and room temperature, photo degradation test in light
and dark and standard stock solution stability 2–8 1C, two aqueous
mixtures were prepared, one from the stability standard stock solution
and the other from fresh standard stock solution (comparison stock).
The response of stability dilution (already stored at room temperature,
refrigerator temperature and in presence of light and dark) against the
comparison dilution (prepared from freshly prepared stock solution) has
been corrected using a correction factor. Six replicates of aqueous
mixture from stability stock and comparison stock were injected.
Correction factor¼ ðConc: of fresh standard solutionÞ
=ðConc: of stability standard solutionÞ
Corrected response¼ Stability stock response Correction factor
% Change¼ ðMean response of comparison samples
−Mean corrected response of stability samplesÞ
=ðMean response of comparision samplesÞ  100
The effect of potentially interfering drugs ( Ibuprofen, Caffeine,
Acetaminophen and Acetyl salicylic acid) on CN and HCT analysis
was performed by spiking PID's at their approximately Cmax in the
LLOQ samples in triplicate. Robustness experiment was performed at
low and high pH of buffer solutions, at different column oven
temperatures (38 1C and 42 1C) and at different ﬂow rates (0.840 mL/
min and 0.760 mL/min). To evaluate ruggedness, precision and
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using different columns and different sets of solutions.2.6. Bioequivalence study design
The bioequivalence study design comprised of a randomized, balanced,
open label, two treatment, two period, two sequence, single dose,
crossover, bioequivalence study by comparing in-house developed test
product i.e., CNC and HCT (32+25 mg) immediate release tablets with
reference product Atacand HCTs (CNC−HCT) (32+25 mg) immedi-
ate release tablets of Astra Zeneca LP, Wilmington, in healthy adult,
human subjects, under fasting conditions. The protocol was approved
by the relevant institutional ethics committee. All participants gave
written consent and were informed of the aims and risks of the study.
Inclusion criteria comprise age (18–45 years), body mass index (18.5–
30.0 kg/height2) and absence of abnormalities on physical examination
along with normal electrocardiogram and laboratory tests. Exclusion
criteria comprise allergy to CNC, HCT, alcoholism, psychosis,
smoking, diabetes or any disease which could compromise the
haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, and
respiratory or central nervous systems. Moreover, all the procedures
were based on the International Conference on Harmonization, E6
Good Clinical Practice guidelines [8]. As per the study protocol 1976
(38 subjects 26 time points 2 periods) clinical blood samples were
to be collected from 38 subjects during two periods of the study. The
clinical blood samples were collected in K2EDTA vacutainer from the
subjects and intermediately stored in deep freezer at −20 1C on theFig. 1 The product ion mass spectra of the [M−H]−days of plasma sample collection. Plasma was obtained by centrifuga-
tion at 4000 rpm at 4 1C for 15 min and stored at −20 1C until assay.
All pharmacokinetic values were gained by the non-compartmental
model and expressed as mean7SD.3. Results and discussion
3.1. LC–MS/MS settings
Internal standards CN d4 (IS1) and HCT
13Cd2 (IS2) were expected
showing nearly similar chromatographic behavior as of analytes
because they were differing only in terms of possessing different
isotopic atoms. The retention time (RT) of IS1 and CN was found
to be 0.88 min and 0.89 min while RT for IS2 and HCT was found
to be 1.14 min and 1.13 min. Furthermore, as expected the
recovery of both the internal standards was similar to that of their
parent compounds. Electron spray ionization (ESI) provided high
ionization efﬁciencies for both analytes and IS in negative ion
mode which resulted in higher sensitivity of the method. The
product ion mass spectra of the [M−H]− ions for HCT and CN and
their respective internal standards have been shown in Fig. 1.3.2. Sample preparation
Liquid–liquid extraction (LLE) method was used for sample
preparation because of relatively low cost, good extractionions of (A) IS1, (B) CN, (C) IS2 and (D) HCT.
B. Singh et al.148efﬁciency as well as simple procedure. Various extraction solvent
systems were tried but mixture of tert-butyl-methyl-ether and
dichloromethane in the ratio of 70:30 (v/v) was found to be the
most effective for extraction of both analytes and IS.
3.3. Method validation
3.3.1. Selectivity
Fig. 2 consists of typical MRM chromatograms of a blank plasma
sample, a plasma sample spiked with CN and HCT at the LLOQ
level (1.00 ng/mL for both analytes) and a plasma sample from a
healthy volunteer 1.5 h after the oral administration of the
combination tablet. There was no signiﬁcant interference from
endogenous substances observed at the retention time of the
analytes and internal standards in the extracted blank plasma
sample.
3.3.2. Sensitivity and linearity
In sensitivity the observed accuracies were 110.17% and 103.50%
with a precision of 4.60% and 3.29% for CN and HCT
respectively. The assay was linear over the concentration range
1.00–499.15 ng/mL for CN and 1.00–601.61 ng/mL for HCT. The
observed slope, intercept and r2 for CN were respectively 0.0083,
0.0163 and 0.9980 while for HCT were 0.0160, 0.0059 and
0.9990. Therefore, the typical equations of calibration curves are
as follows:
CN : y¼ 0:0083xþ 0:0163 ðr2 ¼ 0:9980Þ
HCT : y¼ 0:0160xþ 0:0059 ðr2 ¼ 0:9990Þ
where y represents the analyte/IS peak area ratio and x represents
the plasma concentration of the analyte. LLOQ was 1.00 ng/mLFig. 2 Representative MRM chromatograms of blank plasma sample (A1
LLOQ level (1.00 ng/mL for both analytes) and a plasma sample from a h
tablet. (C1 for CN and C2 for HCT). CN (left panels A1, B1 and C1) and i
B2and C2) and its ISTD-HCT 13Cd2 (right panels A2, B2 and C2).for both CN and HCT and was adequate for clinical PK studies
following oral administration of therapeutic doses for all available
formulations of Atacand HCTs.
3.3.3. Matrix effect
The percentage matrix effects of low and high QC samples were
6.16 and 2.31 for CN while 6.44 and 2.49 for HCT respectively. It
was found to be 6.79 and 1.57 for IS1 and 7.27 and 3.72 for IS2
respectively. The results were within the acceptance criteria and
indicate that ion suppression or enhancement due to the plasma
matrix was consistent and would not interfere with the quantitation
of analytes.
3.3.4. Precision and accuracy
Table 1 summarizes back calculated concentrations of calibration
curve standards for CN and HCT whereas Table 2 represents the
intra-day and inter-day precision and accuracy data. The intra-day
precision for CN was ≤4.95% and accuracy was ≥94.01%. An
intra-day precision for HCT was ≤7.04% and accuracy was
≥94.55%.
Whereas the inter-day precision for CN was ≤4.65% and
accuracy was ≥97.41%. An inter-day precision for HCT was
≤6.62% and accuracy was ≥97.62%.
3.3.5. Recovery and stability
The mean recoveries of CN in low, medium and high QC samples
were 89.02%, 96.90% and 112.19%, respectively (mean
recovery¼99.37711.86%) and those of HCT were 100.65%,
94.16% and 102.49% (mean recovery¼99.1074.41%). Mean
recoveries of IS1 and IS2 were 99.91710.74% and
98.4574.40%, respectively. The data show that the simple LLEand A2), a plasma sample spiked with CN (B1) and HCT (B2) at the
ealthy volunteer 1.5 h after the oral administration of the combination
ts ISTD-CN d4 (right panels A1, B1and C1) and HCT (left panels A2,
Candesartan and hydrochlorothiazide quantitation by UPLC–MS/MS in plasma 149procedure efﬁciently extracts all four compounds from human
plasma. Table 3 summarizes stability data and shows there were no
stability-related issues that might cause problems in application of
the assay to pharmacokinetic study.3.3.6. Other parameters
The outcomes of other parameters like ruggedness, reinjection
reproducibility, effect of potential interfering drugs (PID),
dilution integrity, extended batch veriﬁcation and robustness were
found to be within the acceptance criteria as per the USFDA
guidelines [15].3.4. Bioequivalence study
The method was applied for the analysis of plasma samples
obtained from the pharmacokinetic study. The study wasTable 1 Back calculated concentration of calibration curve standard
Analyte Standard concentration (ng/mL) Mean (ng/mL)
Candesartan 1.00 1.06
2.00 2.08
62.93 67.55
125.61 128.52
225.12 224.26
324.15 310.19
425.57 404.11
499.15 488.92
Hydrochlorothiazide 1.00 1.05
2.00 2.10
75.02 79.34
149.44 148.36
270.73 274.59
390.05 380.98
511.37 491.30
601.61 600.15
Table 2 Inter-day and intra-day precision and accuracy of the meth
Analyte Level Concentration added
(ng/mL)
Inter-day (n¼6)
Mean conc. found
(ng/mL)
Candesartan LLOQQC 1.00 1.03
LQC 2.75 2.72
MQC 249.66 235.09
HQC 411.44 386.78
Hydrochloro-
thiazide
LLOQQC 1.00 1.00
LQC 2.74 2.66
MQC 301.90 292.56
HQC 495.12 468.15conducted as a randomized, balanced, open label, two
treatment, two period, two sequence, single dose, crossover,
bioequivalence study of comparing test product [CNC and
HCT 32+25 mg immediate release tablet] with reference
product [Atacand HCTs (CNC and HCT) 32+25 mg immediate
release tablets] in 59 healthy adult, human subjects, under
fasting conditions. Each subject received a tablet of CNC
(32 mg) and HCT (25 mg) of test or reference product and a
wash out period of 7 days was maintained between two con-
secutive administrations of the investigational products. Blood
samples were collected using K2EDTA vaccutainers at the
following time points: Pre-dose and at 0.50, 1.00, 1.50, 1.75,
2.00, 2.33, 2.67, 3.00, 3.25, 3.50, 3.75, 4.00, 4.33, 4.67, 5.00,
5.50, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and
72.00 h postdose. Pharmacokinetic parameters were calculated
from the subjects who had successfully completed periods I and
II of the study. Some of the main pharmacokinetic parameters ares for candesartan and hydrochlorothiazide (n¼3).
SD CV (%) Nominal (%) Slope Intercept r2
0.04 3.82 105.67 0.0083 0.0163 0.9980
0.04 1.69 104.17
1.58 2.34 107.34
1.98 1.54 102.32
2.24 1.00 99.62
5.26 1.70 95.69
4.10 1.01 94.96
4.96 1.01 97.95
0.07 6.22 104.67 0.0160 0.0059 0.9990
0.04 2.08 105.00
1.14 1.44 105.76
2.61 1.76 99.28
1.63 0.59 101.42
4.40 1.16 97.67
9.66 1.97 96.07
6.54 1.09 99.76
od for candesartan and hydrochlorothiazide.
Intra-day (n¼18)
Nominal
(%)
CV
(%)
Mean conc. found
(ng/mL)
Nominal
(%)
CV
(%)
102.67 4.95 1.03 102.67 4.65
98.91 3.26 2.68 97.41 4.13
94.16 2.56 245.21 98.22 3.88
94.01 2.87 402.50 97.83 3.67
100.17 7.04 1.00 100.17 6.62
97.02 4.67 2.70 98.52 3.71
96.91 2.39 305.45 101.17 4.12
94.55 3.20 483.36 97.62 3.16
Table 3 Stability data of CN and HCT in processed QC samples for different stability activities at different conditions (n¼6).
Stability
experiment
Analyte Concentration
added (ng/mL)
Mean concentration
found in stability
samples (ng/mL)
Nominal
(%)
CV
(%)
Mean concentration found
in comparison samples
(ng/mL)
Nominal
(%)
CV
(%)
Change
(%)
Bench top stability
(22 h)
CN 2.75 2.71 98.67 2.97 2.58 93.82 4.71 6.10
411.44 402.84 97.91 2.98 399.52 97.12 1.78 −0.81
HCT 2.74 2.69 98.18 0.94 2.48 90.63 3.37 −0.17
495.12 476.11 96.16 2.32 473.41 95.69 3.63 −0.49
Auto sampler
stability (50 h)
CN 2.75 2.69 97.76 2.04 2.57 93.33 5.10 4.19
411.44 390.53 94.92 2.63 405.07 98.47 3.44 3.60
HCT 2.74 2.71 99.03 2.97 2.65 96.87 3.45 2.67
495.12 473.16 95.56 2.30 474.55 95.92 2.41 0.37
Freeze–thaw
stability (5-
cycles)
CN 2.75 2.78 101.15 1.60 2.58 93.82 4.71 −0.42
411.44 401.52 97.59 2.67 399.52 97.12 1.78 −0.48
HCT 2.74 2.70 98.24 2.26 2.48 90.63 3.37 −0.37
495.12 480.11 96.97 0.32 473.41 95.69 3.63 −1.34
Dry extract
stability (69 h)
CN 2.75 2.74 99.58 3.54 2.57 93.33 5.10 1.33
411.44 404.22 98.25 2.27 405.07 98.47 3.44 0.23
HCT 2.74 2.69 98.11 2.04 2.65 96.87 3.45 2.51
495.12 470.54 95.03 1.58 474.55 95.92 2.41 0.92
Wet extract
stability (69 h)
CN 2.75 2.75 99.82 3.33 2.57 93.33 5.10 2.56
411.44 411.24 99.95 0.54 405.07 98.47 3.44 −1.51
HCT 2.74 2.68 97.93 1.17 2.65 96.87 3.45 −0.06
495.12 472.49 95.43 2.28 474.55 95.92 2.41 0.51
Lipemic plasma
stability (4 days)
CN 2.75 2.77 100.61 4.34 2.58 93.82 4.71 0.87
411.44 406.56 98.81 1.58 399.52 97.12 1.78 −1.74
HCT 2.74 2.74 99.94 3.54 2.48 90.63 3.37 −1.58
495.12 481.39 97.23 1.90 473.41 95.69 3.63 −1.61
Haemolysed
plasma stability
(4 days)
CN 2.75 2.71 98.61 3.94 2.58 93.82 4.71 4.75
411.44 409.87 99.62 1.53 399.52 97.12 1.78 −2.57
HCT 2.74 2.69 98.11 2.04 2.48 90.63 3.37 2.95
495.12 486.11 98.18 1.30 473.41 95.69 3.63 −2.60
Long term stability
at −65710 1C
(22 days)
CN 2.75 2.69 97.88 2.26 2.50 90.97 1.28 0.70
411.44 384.37 93.42 1.07 383.30 93.21 0.64 −0.22
HCT 2.74 2.77 100.97 4.34 2.58 94.16 2.88 −2.33
495.12 465.62 94.04 0.85 462.62 93.44 0.92 −0.65
Long term stability
at −2275 1C (22
days)
CN 2.75 2.69 97.82 0.94 2.50 90.97 1.28 2.20
411.44 381.22 92.66 1.20 383.30 93.21 0.64 0.60
HCT 2.74 2.71 98.97 3.94 2.58 94.16 2.88 −3.55
495.12 465.19 93.95 1.39 462.62 93.44 0.92 −0.55
B. Singh et al.150given in Table 4. The mean plasma concentration versus time
proﬁle is shown in Fig. 3.4. Conclusion
As shown above, the CN and HCT compounds are highly stable
in biological matrix when experiments were performed underdifferent stability conditions like bench top, freeze–thaw, long
term (−65 1C and −22 1C) and auto sampler etc. The recovery of
the method is very good with no matrix effect. Due to the extended
calibration curve range (at both LLOQ and ULOQ levels) the
method could be utilized to quantify CN and HCT for all available
dose strengths. Due to short analysis run time (2 min) and low
plasma sample volume consumption (0.1 mL) the method is highly
economical in comparison to all the published literature. The
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Fig. 3 Mean plasma concentration–time curve for CN (A) and HCT
(B) compared with standard (Atacand HCTs).
Candesartan and hydrochlorothiazide quantitation by UPLC–MS/MS in plasma 151method has been successfully used in a pharmacokinetic study,
where 59 healthy male volunteers were given a ﬁxed-dose of CNC
+HCT (32+25 mg) immediate release tablet. Furthermore, another
added advantage, a single analytical column was used to chroma-
tograph about 3500 extracts and there was no requirement to clean
this column during the entire study sample analysis.
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